background
novel
swineorigin
influenza
viru
detect
worldwid
april
world
health
organ
declar
global
pandem
june
dna
vaccin
prime
improv
respons
inactiv
influenza
vaccin
describ
rapid
product
clinic
evalu
dna
vaccin
encod
hemagglutinin
protein
pandem
influenza
viru
accomplish
nearli
two
month
faster
product
licens
monoval
inactiv
vaccin
miv
method
subject
receiv
three
dna
vaccin
mg
intramuscularli
biojector
interv
eighteen
subject
receiv
option
boost
licens
miv
becam
avail
interv
third
dna
inject
miv
boost
week
vaccin
safeti
assess
clinic
observ
laboratori
paramet
solicit
reactogen
antibodi
respons
assess
elisa
hai
neutral
assay
cell
respons
elispot
flow
cytometri
vaccin
safe
welltoler
evalu
hai
develop
posit
respons
week
third
dna
inject
week
miv
boost
similar
result
detect
neutral
assay
cell
respons
detect
dna
miv
antibodi
respons
significantli
amplifi
miv
boost
howev
boost
increas
cell
respons
induc
dna
vaccin
dna
vaccin
produc
quickli
welltoler
modest
immunogen
singl
agent
ha
dna
primemiv
boost
regimen
util
one
dna
prime
vaccin
longer
boost
interv
shown
signific
immunogen
rapid
largescal
product
ha
dna
vaccin
potenti
contribut
effici
respons
futur
influenza
pandem
annual
season
influenza
epidem
caus
death
major
person
age
older
licens
season
influenza
vaccin
provid
moder
protect
influenza
take
signific
resourc
time
manufactur
year
april
novel
swineorigin
influenza
viru
soiv
identifi
june
world
health
organ
declar
global
pandem
underway
pandem
influenza
vaccin
manufactur
enabl
swift
genom
identif
food
drug
administr
fda
support
strain
chang
pathway
licensur
vaccin
manufactur
develop
prototyp
vaccin
august
receiv
fda
approv
septemb
one
addit
vaccin
approv
novemb
despit
rapid
action
vaccin
product
avail
winter
season
southern
hemispher
vaccin
made
avail
public
demonstr
robust
immunogen
subsequ
clinic
studi
emerg
experi
pandem
influenza
viru
well
continu
antigen
evolut
known
influenza
strain
togeth
emphas
need
streamlin
influenza
vaccin
develop
plasmid
dnabas
vaccin
demonstr
preclin
efficaci
rel
rapid
manufactur
process
plasmid
dna
quickli
modifi
carri
antigen
interest
recombin
dna
technolog
allow
much
faster
develop
product
vaccin
candid
base
viral
genom
sequenc
tradit
vaccin
product
method
test
potenti
vaccin
candid
phase
clinic
studi
rapidli
provid
data
immunogen
novel
influenza
hemagglutinin
clarifi
exposur
influenza
strain
may
offer
cross
protect
speed
given
vaccin
develop
product
meet
public
demand
regardless
immunogen
vaccin
effect
halt
pandem
improv
effici
vaccin
product
import
aspect
influenza
vaccin
develop
could
help
meet
demand
rapid
widespread
protect
immun
futur
pandem
report
result
phase
studi
evalu
safeti
immunogen
pandem
dna
vaccin
without
boost
licens
pandem
miv
given
week
later
safeti
immunogen
investig
dna
vaccin
follow
miv
boost
evalu
pandem
monoval
inactiv
vaccin
miv
becam
avail
offer
protocol
amend
administr
booster
subject
safeti
monitor
evalu
laboratori
clinic
find
studi
visit
advers
event
code
medic
dictionari
regulatori
activ
meddra
assess
sever
use
scale
develop
divis
aid
niaid
adapt
healthi
volunt
studi
solicit
local
system
reactogen
symptom
collect
day
follow
vaccin
advers
event
record
day
final
dna
vaccin
administ
day
follow
licens
miv
vaccin
pandem
dna
plasmid
vaccin
manufactur
vrcniaidvaccin
pilot
plant
oper
saicfrederick
frederick
md
cgmp
vaccin
compos
singl
close
circular
dna
plasmid
encod
hemagglutinin
ha
protein
pandem
influenza
viru
control
cmvr
promot
insert
genbank
use
master
cell
bank
mcb
synthes
vrc
use
blue
heron
biotechnolog
inc
bothel
wa
human
prefer
codon
previous
describ
plasmid
use
transform
escherichia
coli
bacteri
host
strain
order
produc
master
cell
bank
mcb
mcb
expand
cultur
inocul
ferment
product
bacteri
cell
growth
depend
upon
cellular
express
kanamycin
resist
protein
encod
portion
plasmid
dna
follow
growth
bacteri
cell
express
plasmid
plasmid
dna
purifi
cellular
compon
concentr
filter
membran
store
formul
drug
product
drug
product
fill
mgml
phosphat
buffer
salin
pb
ml
vial
commerci
avail
licens
pandem
influenza
vaccin
manufactur
sanofi
pasteur
inc
n
novarti
vaccin
diagnost
inc
n
administ
needl
syring
deltoid
muscl
detect
antibodi
hai
assay
base
previous
describ
method
optim
detect
antibodi
pandem
influenza
hai
assay
perform
vbottom
plate
use
four
hemagglutin
unit
hau
viru
turkey
rbc
previous
describ
viru
strain
genet
antigen
similar
prototyp
vaccin
viru
use
hai
assay
perform
cdc
influenza
branch
atlanta
ga
respons
assess
posit
baselin
prevaccin
titer
greater
subject
neg
baselin
postvaccin
titer
assess
posit
valu
greater
subject
posit
baselin
postvaccin
titer
assess
posit
valu
least
increas
titer
baselin
endpoint
titer
antibodi
direct
antigen
protein
scienc
corpor
meriden
ct
determin
use
dynex
technolog
plate
coat
prepar
purifi
recombin
protein
accord
method
adapt
previous
describ
endpoint
titer
calcul
dilut
serum
concentr
gave
optic
densiti
read
background
elisa
endpoint
titer
assess
posit
valu
subtract
baselin
prevaccin
valu
greater
equal
neutral
antibodi
evalu
capac
sera
prevent
infect
cell
replicationincompet
hapseudotyp
viru
pseudotyp
viru
express
ha
na
antigen
luciferas
report
gene
neutral
activ
quantifi
rel
decreas
luciferas
activ
compar
infect
cell
absenc
sera
base
previous
describ
method
respons
assess
posit
neutral
titer
increas
least
four
fold
prevaccin
valu
cell
respons
assess
intracellular
cytokin
stain
ic
elispot
previous
describ
vaccineinduc
cell
respons
detect
elispot
use
commerci
avail
elispot
kit
mabtech
result
express
mean
spotform
cell
sfc
per
million
pbmc
respons
consid
posit
met
follow
criteria
number
spot
per
cell
minu
background
exceed
pbmc
nonbackground
correct
mean
least
four
fold
greater
mean
neg
stimul
sampl
vaccineinduc
cell
respons
consid
posit
ic
follow
criteria
met
fisher
exact
test
tabl
consist
posit
neg
cell
peptid
neg
control
onesid
pvalu
less
percent
posit
cell
peptid
minu
percent
posit
cell
neg
control
background
subtract
percent
exceed
follow
cell
cell
cell
intentiontotreat
analys
appli
endpoint
report
posit
immunogen
respons
rate
exact
confid
interv
pearsonclopp
method
magnitud
immun
respons
report
geometr
mean
antibodi
respons
arithmet
mean
cell
respons
along
confid
interv
statist
analys
perform
use
statist
analysi
system
sa
r
statist
softwar
formal
multipl
comparison
adjust
employ
safeti
endpoint
secondari
endpoint
ind
singl
plasmid
dna
vaccin
encod
hemagglutinin
ha
protein
pandem
influenza
submit
niaid
juli
day
us
declar
pandem
influenza
public
health
emerg
first
dna
vaccin
administ
august
enrol
subject
complet
novemb
complet
three
dna
vaccin
vrc
studi
timelin
relat
vaccin
manufactur
influenza
pandem
shown
fig
limit
suppli
licens
miv
becam
avail
distribut
octob
restrict
highrisk
popul
health
care
worker
vaccin
becam
avail
januari
time
subject
subject
receiv
miv
outsid
studi
complet
reactogen
evalu
provid
blood
immunogen
test
followup
studi
visit
opt
receiv
miv
result
boost
interv
rang
week
last
dna
inject
last
miv
administ
februari
last
studi
visit
complet
june
twenti
healthi
subject
age
year
enrol
studi
subject
femal
mean
age
subject
year
mean
bmi
rang
tabl
vaccin
reactogen
summar
tabl
vaccinerel
seriou
advers
event
sae
new
chronic
medic
condit
report
ae
mild
moder
sever
four
grade
advers
event
attribut
relat
dna
vaccin
administr
migrain
day
post
vaccin
case
eros
site
inject
day
vaccin
resolv
without
residu
effect
two
case
influenzalik
ill
ili
report
studi
grade
ili
day
third
dna
administr
grade
ili
day
miv
boost
overal
vaccin
welltoler
sever
reactogen
report
immun
respons
vaccin
measur
hai
neutral
assay
elisa
elispot
assay
summar
fig
antibodi
respons
modest
dna
immun
case
improv
miv
boost
evalu
hai
subject
develop
posit
respons
week
last
dna
number
rose
week
miv
boost
similar
result
detect
neutral
assay
posit
respons
dna
inject
rose
week
post
miv
boost
measur
elisa
subject
develop
posit
respons
week
post
last
dna
posit
week
miv
boost
evalu
ic
cell
respons
robust
respons
prior
vaccin
one
subject
cell
posit
one
subject
cell
posit
statist
signific
increas
magnitud
cell
respons
observ
week
post
last
dna
inject
determin
elispot
fig
p
magnitud
frequenc
cell
respons
increas
miv
boost
fig
dna
alon
subject
posit
respons
subject
remain
posit
miv
boost
cumul
posit
respons
rate
ic
cell
cumul
cell
respons
less
cytokin
test
subject
preexist
influenza
respons
measur
hai
posit
hai
respons
baselin
posit
hai
respons
dna
prime
compar
neg
baselin
hai
respons
posit
hai
respons
miv
compar
neg
baselin
hai
respons
investig
dna
vaccin
demonstr
potenti
rapid
dna
vaccin
product
respons
pandem
vaccin
investig
dna
vaccin
alon
boost
miv
safe
well
toler
dna
vaccin
immunogen
singl
agent
demonstr
modest
immunogen
find
consist
current
understand
full
effect
dna
vaccin
prime
immun
respons
may
evid
boost
inactiv
vaccin
interpret
immunogen
result
studi
limit
circumst
small
phase
studi
conduct
preclud
inclus
miv
control
group
likestrain
match
miv
avail
month
studi
began
addit
studi
design
compar
respons
dna
miv
vaccin
subject
base
upon
presenc
absenc
preexist
influenza
respons
number
subject
small
draw
firm
conclus
regard
issu
immunogen
significantli
improv
miv
boost
measur
vaccin
induc
antibodytest
paramet
consist
find
prior
primeboost
studi
find
suggest
investig
dna
vaccin
may
use
primeboost
regimen
combin
miv
studi
perform
group
sinc
complet
studi
demonstr
durat
primeboost
interv
crucial
induc
immunogen
interv
week
ideal
shorter
interv
produc
modest
respons
similar
seen
respons
dna
vaccin
alon
use
anoth
potenti
pandem
strain
singl
dose
dna
prime
effect
miv
boost
given
interv
least
week
find
consist
work
earlier
vaccin
trial
includ
studi
hbv
vaccin
evalu
sampl
dna
studi
indic
dna
prime
expand
antibodi
epitop
repertoir
increas
affin
matur
boostintervaldepend
manner
adult
singl
dose
dna
util
week
primeboost
interv
overal
regimen
current
studi
would
shorten
postul
immunogen
would
significantli
improv
rang
interv
dna
prime
miv
boost
wide
studi
size
allow
us
comment
directli
conclus
effect
boost
interv
current
studi
contrast
modest
effect
dna
prime
alon
antibodi
titer
dna
plasmid
vaccin
induc
statist
signific
cell
respons
absenc
miv
boost
provid
measur
evid
dna
vaccin
induc
prime
effect
prior
work
dna
vaccin
demonstr
improv
immunogen
use
adjuv
andor
altern
deliveri
devic
trial
use
one
devic
biojector
shown
improv
immunogen
dna
vaccin
improv
respons
also
observ
human
clinic
trial
dna
vaccin
deliv
gene
gun
electropor
accompani
adjuv
perhap
futur
trial
one
altern
could
employ
rather
miv
boost
improv
immun
induc
vaccin
pandem
situat
dna
plasmid
inactiv
viral
vaccin
could
combin
improv
overal
protect
immun
respons
influenza
pandem
dna
plasmid
vaccin
advantag
quick
design
effici
product
tradit
method
miv
product
depend
upon
incub
chicken
egg
eventu
produc
approxim
one
dose
per
egg
dna
plasmid
vaccin
produc
use
e
coli
bioreactor
capac
order
thousand
liter
dna
plasmid
vaccin
design
product
depend
select
growth
chicken
egg
even
cell
cultur
eggfre
strategi
overal
product
endpoint
abil
produc
million
dose
monoval
dna
vaccin
product
within
one
month
futur
pandem
set
speed
product
dna
plasmid
vaccin
could
util
rapidli
administ
initi
prime
dose
time
tradit
produc
inactiv
flu
vaccin
becam
commerci
avail
could
use
week
booster
immun
regimen
novel
pandem
strain
inactiv
viral
vaccin
would
use
boost
reduc
demand
product
yield
low
strategi
har
speed
effici
dna
plasmid
product
combin
convent
miv
vaccin
boost
potenti
improv
respons
time
new
emerg
pandem
influenza
threat
support
inform
consort
checklist
doc
protocol
vrc
nih
pdf
